Andrew Harrison, MD
Ophthalmic Plastic and Reconstructive Surgery · Minneapolis, MNNPI 1396768180
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,084 of the $237,781 with a category attached, or 65.2%. Amgen accounts for 88.7% of it on its own, with 9 other manufacturers making up the rest.
Across 247 payments — averaging $962.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$211K
- Argenx US, Inc.$18K
- Osmotica Pharmaceutical Corp.$5K
- Vertical Pharmaceuticals, LLC$2K
- AbbVie$637
- Revance Therapeutics, Inc.$348
- plus $526 from 4 others
What the payments were for
- Consulting fees$48,76421%
- Speaking & faculty fees$155,08465%
- Travel & lodging$29,31312%
- Food & beverage$4,6102%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 212 | $210,953 |
| Argenx US, Inc. | 14 | $18,217 |
| Osmotica Pharmaceutical Corp. | 2 | $4,615 |
| Vertical Pharmaceuticals, LLC | 2 | $2,485 |
| AbbVie(2 entities) | 8 | $637 |
| Revance Therapeutics, Inc. | 2 | $348 |
| Stryker | 4 | $239 |
| Galderma Laboratories, L.p. | 1 | $143 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Oyster Point Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$199,124
- VYVGART HYTRULO$16,188
- VYVGART$1,800
- DAXXIFY$348
- VUITY$148
- BOTOX$145
- REZUROCK$125
- MEDPOR TITAN$107
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 243 | $2,791 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 124 | $1,618 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 124 | $377 |
| Prednisolone Acetate | 11 | $358 |
| Cephalexin | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Minneapolis
- Ali MokhtarzadehMinneapolis$7K
- Adam NeuhouserMinneapolis$428
- Phillip RadkeMinnetonka$42K
- Jill Melicher LarsonBloomington$290
- Eric NelsonEdina$272
- William LiphamBloomington$200
- Mohit DewanWoodbury$85
- Douglas DworakWoodbury$69
- Nishanth IyengarRochester$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.